A Confirmatory, Dual Center Nonhuman Primate Study on the Efficacy of Novel Oropharyngeal Spray Immunization With an Adenoviral Vector Vaccine Against RSV-Important Lessons Learned.
5 affiliations
- 1Harald zur Hausen Institute of Virology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
- 2FAU Profile Center Immunomedicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- 3Biomedical Primate Research Centre, Rijswijk, the Netherlands.
- 4German Primate Center, Göttingen, Germany.
- 5Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Abstract
Background
In a randomized, blinded, dual center study across two European primate research facilities, we evaluated the immunogenicity and protective efficacy of a DNA prime-oropharyngeal adenoviral boost vaccination strategy against respiratory syncytial virus (RSV).Methods
Rhesus macaques received an RSV fusion protein (F) DNA vaccine via electroporation, followed by two mucosal administrations of a recombinant adenovirus vector encoding the same antigen. Mock-vaccinated animals and a comparator group mimicking natural immunity induced by primary RSV infection were included as controls. Systemic and mucosal immune responses were monitored longitudinally.Results
We detected robust cellular and humoral immune responses, but with some variability between the two centers. Nevertheless, RSV-vaccinated animals demonstrated markedly reduced viral replication in the upper and lower respiratory tract after RSV challenge infection. Unexpected RSV-specific immunity in the control group at one single study site prevented confirmation of the predefined primary endpoint.Conclusion
Our results support the potential of mucosal adenoviral boosting following DNA priming to induce protective immunity against RSV, while highlighting challenges associated with multi-center preclinical vaccine studies.
Related
- Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD
- Intranasal adenoviral neuraminidase vaccine induces local and systemic immunity and homosubtypic protection against influenza A viruses
- Decoding the anti-adenoviral potential of Ocimum volatile organic compounds: linking chemical fingerprints to molecular targets via docking
- Immunogenicity and protective efficacy of single-dose adenoviral vaccines expressing Crimean-Congo haemorrhagic fever virus GP38, Gc, or nucleoprotein antigens in mice: a preclinical study
- Cricopharyngeal peroral endoscopic myotomy for the treatment of a cricopharyngeal bar causing oropharyngeal dysphagia.
BibTeX
@article{tenbusch2026confirmatory,
title = {{A Confirmatory, Dual Center Nonhuman Primate Study on the Efficacy of Novel Oropharyngeal Spray Immunization With an Adenoviral Vector Vaccine Against RSV-Important Lessons Learned.}},
author = {Matthias Tenbusch and Gerrit Koopman and Petra Mooij and Berit Roshani and Pascal Irrgang and Dennis Lapuente and Ivanela Kondova and Willy M Bogers and Edmond J Remarque and Ramona Vestweber and Samuel Alberto Merida Ruiz and Nadine Krüger and Sebastian Meyer and Olaf Gefeller and Christiane Stahl-Hennig and Klaus Überla},
journal = {Journal of medical primatology},
year = {2026},
month = oct,
doi = {10.1111/jmp.70121},
url = {https://europepmc.org/article/MED/42899948},
note = {CC BY},
}
RIS
TY - JOUR
TI - A Confirmatory, Dual Center Nonhuman Primate Study on the Efficacy of Novel Oropharyngeal Spray Immunization With an Adenoviral Vector Vaccine Against RSV-Important Lessons Learned.
AU - Matthias Tenbusch
AU - Gerrit Koopman
AU - Petra Mooij
AU - Berit Roshani
AU - Pascal Irrgang
AU - Dennis Lapuente
AU - Ivanela Kondova
AU - Willy M Bogers
AU - Edmond J Remarque
AU - Ramona Vestweber
AU - Samuel Alberto Merida Ruiz
AU - Nadine Krüger
AU - Sebastian Meyer
AU - Olaf Gefeller
AU - Christiane Stahl-Hennig
AU - Klaus Überla
PY - 2026
DA - 2026/10/30
JO - Journal of medical primatology
DO - 10.1111/jmp.70121
UR - https://europepmc.org/article/MED/42899948
AB - Background In a randomized, blinded, dual center study across two European primate research facilities, we evaluated the immunogenicity and protective efficacy of a DNA prime-oropharyngeal adenoviral boost vaccination strategy against respiratory syncytial virus (RSV).Methods Rhesus macaques received an RSV fusion protein (F) DNA vaccine via electroporation, followed by two mucosal administrations of a recombinant adenovirus vector encoding the same antigen. Mock-vaccinated animals and a comparator group mimicking natural immunity induced by primary RSV infection were included as controls. Systemic and mucosal immune responses were monitored longitudinally.Results We detected robust cellular and humoral immune responses, but with some variability between the two centers. Nevertheless, RSV-vaccinated animals demonstrated markedly reduced viral replication in the upper and lower respiratory tract after RSV challenge infection. Unexpected RSV-specific immunity in the control group at one single study site prevented confirmation of the predefined primary endpoint.Conclusion Our results support the potential of mucosal adenoviral boosting following DNA priming to induce protective immunity against RSV, while highlighting challenges associated with multi-center preclinical vaccine studies.
SN - 0047-2565
SN - 1600-0684
ER -